AzTrials
AzTrials

Urinary StoneRISUS_AINCT06412900

Radiomics and Image Segmentation of Urinary Stones by Artificial Intelligence

An observational study of Urinary Stone and Renal Colic, run by Oslo University Hospital at 1 site in Norway.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record
Search all trials

Trial summary

Kidney stone disease causes significant morbidity, and stones obstructing the ureter can have serious consequences. Imaging diagnostics with computed tomography (CT) are crucial for diagnosis, treatment selection, and follow-up. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Urinary Stone, Renal Colic, Obstruction Ureter
How many people
522 participants
Where
1 siteNorway
Study dates
21 May 2024to 28 Mar 2028
How long will I take part?
3 Months
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Patients referred for CT for new/acute episode of renal colic and suspicion of /or known urinary stone disease.

Who may be able to join

  • Referral for CT due to episode of renal colic and clinical suspicion of urinary stone disease or
  • Referral for CT due to new episode of pain in patient with known urinary stone disease
  • Age ≥ 18 years

Who cannot join

  • Referral for control CT of asymptomatic patients with known urinary stone disease
  • Referral for control CT after treatment
  • Referral for control CT for spontaneous passage of stone.
  • Lack of informed consent for any reason.

Trial locations and contacts

1 site in 1 country.

Norway1 site
  • Oslo University Hospital, Aker

    Oslo, 0586

Other trials in Norway

About this study

Kidney stone disease causes significant morbidity, and stones obstructing the ureter can have serious consequences. Imaging diagnostics with computed tomography (CT) are crucial for diagnosis, treatment selection, and follow-up. Segmentation of CT images can provide objective data on stone burden and signs of obstruction. Artificial intelligence (AI) can automate such segmentation but can also be used for the diagnosis of stone disease and obstruction.

In this project, the aim is to investigate if:

Read more

Manual segmentation of CT scans can provide more accurate information about kidney stone disease compared to conventional interpretation.

AI segmentation yields valid results compared to manual segmentation. AI can detect ureteral stones and obstruction or predict spontaneous passage.

Read the detailed description

Background:

Goals and Objectives:

The project aims to contribute to personalized and improved treatment and follow-up of patients with kidney stones using radiomics and the development of an artificial intelligence tool for CT examination assessment. The objectives are to assess:

  • Whether manual segmentation of CT images of the urinary tract provides equivalent or more accurate information about kidney stone disease compared to conventional interpretation and reporting.
  • Whether segmentation performed with AI yields valid results compared to manual segmentation.
  • Whether AI can detect ureteral stones and obstruction and/or predict spontaneous passage of stones.

Method:

Cohort:

Patients are recruited to the study at Oslo University Hospital, Radiology Department, Section Aker, which performs approximately 1350 CT examinations for urinary tract stones in approximately 1000 patients each year. Approximately 500 patients with a new episode or newly occurring colic pain and clinical suspicion of kidney stones are expected to be included.

Clinical data (where available):

  • Baseline CT: date and image data
  • Initial treatment (conservative, URS, PCN, ESWL) decision after baseline CT
  • Follow-up CT: date and image data
  • Time to spontaneous stone passage (negative control CT) or completed surgical intervention (URS)
  • Any other surgical/invasive procedure
  • Stone chemical analysis
  • Clinical biochemistry: creatinine/eGFR, CRP, leukocytes (at baseline and follow-ups).

Image data:

Clinical radiology report:

  • Stone: (largest calculus and any obstructing calculus): largest diameter in any plane, density (ROI set by clinical judgment, largest possible ROI - in the slice where the stone is largest), location (upper ureter: above crossing of vessels, lower ureter: below crossing of vessels, ostial: in bladder wall)
  • Renal pelvis: largest diameter of calyx neck lower calyx, clinical assessment of dilation (not dilated/slight/moderate/severe).
  • Segmentation:
  • Stone: total segmented stone volume, largest diameter, and density of segmented stone.
  • Collecting system: total segmented volume of the collecting system and renal pelvis.
Keywords
Urolithiasis, Computed tomography, Image segmentation, Ureteral obstruction, Artificial intelligence
Medical subject headings
Urinary Calculi, Renal Colic, Ureteral Obstruction, Urolithiasis, Ureterolithiasis, Kidney Calculi

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT06412900
Study groupRoleWhat they receive
Adults investigated with CT for suspected urinary stone diseaseNewly occurring colic pain and clinical suspicion of kidney stones or known kidney stone with new/increasing symptoms. Age ≥ 18 years

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Comparison of stone diameter from manual segmentation with radiology report

    Stone diameter (in mm) compared between manual segmentation and radiology report (paired t-test or wilcoxon rank sum test if non-normally distributed data)

    Measured: At time of CT examination (inclusion and follow up - expected average 12 weeks)

  2. Comparison of AI-segmentation of stones (DICE-score) with manual segmentation

    DICE-score for AI-segmentation of stones, compared to manual segmenation (gold standard)

    Measured: At time of CT examination (inclusion and follow up - expected average 12 weeks)

  3. Prospective performance (diagnostic accuracy) of AI detection of ureteral stone (compared to radiology report (gold standard)

    Comparison of differences in dicotomous proportions in paired data according to Newcombe

    Measured: At time of CT examination (inclusion and follow up - expected average 12 weeks)

Secondary outcomes (11)
  1. Comparison of stone density from manual segmentation with radiology report

    Stone density (in Hounsfield Units) compared between manual segmentation and radiology report (paired t-test or wilcoxon rank sum test if non-normally distributed data)

    Measured: At time of CT examination (inclusion and follow up - expected average 12 weeks)

  2. Comparison of distention of renal pelvis from manual segmentation with radiology report

    Distention of renal pelvis (in mm) compared between manual segmentation and radiology report (paired t-test or wilcoxon rank sum test if non-normally distributed data)

    Measured: At time of CT examination (inclusion and follow up - expected average 12 weeks)

  3. Comparison of AI-segmentation of stones (Hausdorff distance) with manual segmentation

    Haussdorff distance for AI-segmentation of stones, compared to manual segmenation (gold standard)

    Measured: At time of CT examination (inclusion and follow up - expected average 12 weeks)

  4. Comparison of AI-segmentation of stones (diagnostic accuracy) with manual segmentation

    Diagnostic accuracy for AI-segmentation of stones compared to manual segmenation (gold standard)

    Measured: At time of CT examination (inclusion and follow up - expected average 12 weeks)

  5. Comparison of AI-segmentation of renal pelvis (Dice-score) with manual segmentation

    DICE-score for AI-segmentation of renal pelvis compared to manual segmenation (gold standard)

    Measured: At time of CT examination (inclusion and follow up - expected average 12 weeks)

  6. Comparison of AI-segmentation of renal pelvis (Hausdorff distance) with manual segmentation

    Hausdorff distance for AI-segmentation of renal pelvis compared to manual segmenation (gold standard)

    Measured: At time of CT examination (inclusion and follow up - expected average 12 weeks)

  7. Comparison of AI-segmentation of renal pelvis (diagnostic accuracy) with manual segmentation

    Diagnostic accuracy for AI-segmentation of renal pelvis compared to manual segmenation (gold standard)

    Measured: At time of CT examination (inclusion and follow up - expected average 12 weeks)

  8. Comparison of AI-segmentation of renal parenchyma (DICE-score) with manual segmentation

    DICE-score for AI-segmentation of renal parenchyma compared to manual segmenation (gold standard)

    Measured: At time of CT examination (inclusion and follow up - expected average 12 weeks)

  9. Comparison of AI-segmentation of renal parenchyma (Hausdorff distance) with manual segmentation

    Hausdorff distance for AI-segmentation of renal parenchyma compared to manual segmenation (gold standard)

    Measured: At time of CT examination (inclusion and follow up - expected average 12 weeks)

  10. Comparison of AI-segmentation of renal parenchyma (diagnostic accuracy) with manual segmentation

    Diagnostic accuracy for AI-segmentation of renal parenchyma compared to manual segmenation (gold standard)

    Measured: At time of CT examination (inclusion and follow up - expected average 12 weeks)

  11. Prospective performance (diagnostic accuracy) of AI detection of ureteral obstruction (compared to radiology report (gold standard)

    Comparison of differences in dicotomous proportions in paired data according to Newcombe

    Measured: At time of CT examination (inclusion and follow up - expected average 12 weeks)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted14 May 2024
  2. Study start21 May 2024
  3. Primary completion2 Aug 2025 (estimated)
  4. Study completion28 Mar 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
522 participants (actual)
Target duration
3 Months
IDs, dates and publications
ClinicalTrials.gov ID
NCT06412900
Sponsor's protocol ID
31347039
Other IDs
660399
Acronym
RISUS_AI
Status last verified
Aug 2025
First submitted
30 Apr 2024
Last updated
11 Aug 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Urinary Stone and Renal Colic, run by Oslo University Hospital at 1 site in Norway.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 11 Aug 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Norway. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Comparison of stone diameter from manual segmentation with radiology report (time frame: At time of CT examination (inclusion and follow up - expected average 12 weeks)). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Aug 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in